Objective evaluation of dextromethorphan and glaucine as antitussive agents.
Twenty-four inpatients affected by chronic cough completed a single-dose double-blind cross-over study of placebo, glaucine 30 mg and dextromethorphan 30 mg. The study was carried out using a balanced incomplete block design, each patient receiving two of the three experimental treatments. Objective evaluation of cough was ensured by means of a writing cough recorder. Coughs after dextromethorphan and glaucine were fewer than coughs after placebo: however only glaucine was significantly different from placebo in reducing coughs. Treatments were well tolerated: clinical results included a reduction in pulse rate after both dextromethorphan and glaucine , and a large number of patients reporting side effects after dextromethorphan administration.
D000328:Adult; D000368:Aged; D000996:Antitussive Agents / Q000627:therapeutic use*; D001060:Aporphines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy*; D003915:Dextromethorphan / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007981:Levorphanol / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011674:Pulse / Q000187:drug effects; D011897:Random Allocation; D012893:Sleep Wake Disorders / Q000139:chemically induced; D014786:Vision Disorders / Q000139:chemically induced
D000996:Antitussive Agents; D001060:Aporphines; D007981:Levorphanol; D003915:Dextromethorphan; C005004:glaucine